These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 8643355)

  • 21. The VP16 transcription activation domain is functional when targeted to a promoter-proximal RNA sequence.
    Tiley LS; Madore SJ; Malim MH; Cullen BR
    Genes Dev; 1992 Nov; 6(11):2077-87. PubMed ID: 1427073
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A dynamic in vivo view of the HIV-I Rev-RRE interaction.
    Charpentier B; Stutz F; Rosbash M
    J Mol Biol; 1997 Mar; 266(5):950-62. PubMed ID: 9086273
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of HIV-1 Rev-RRE interaction by diphenylfuran derivatives.
    Ratmeyer L; Zapp ML; Green MR; Vinayak R; Kumar A; Boykin DW; Wilson WD
    Biochemistry; 1996 Oct; 35(42):13689-96. PubMed ID: 8885849
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Altering the context of an RNA bulge switches the binding specificities of two viral Tat proteins.
    Smith CA; Crotty S; Harada Y; Frankel AD
    Biochemistry; 1998 Jul; 37(30):10808-14. PubMed ID: 9692971
    [TBL] [Abstract][Full Text] [Related]  

  • 25. RNA recognition and regulation of HIV-1 gene expression by viral factor Tat.
    Naryshkin NA; Gait MJ; Ivanovskaya MG
    Biochemistry (Mosc); 1998 May; 63(5):489-503. PubMed ID: 9632883
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HIV-1 regulatory protein tat induces RNA binding proteins in central nervous system cells that associate with the viral trans-acting-response regulatory motif.
    Kundu M; Ansari SA; Chepenik LG; Pomerantz RJ; Khalili K; Rappaport J; Amini S
    J Hum Virol; 1999; 2(2):72-80. PubMed ID: 10225209
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interaction of HIV Tat model peptides with tRNA and 5S rRNA.
    Giel-Pietraszuk M; Barciszewska MZ; Mucha P; Rekowski P; Kupryszewski G; Barciszewski J
    Acta Biochim Pol; 1997; 44(3):591-600. PubMed ID: 9511968
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sequence requirements for Rev multimerization in vivo.
    Madore SJ; Tiley LS; Malim MH; Cullen BR
    Virology; 1994 Jul; 202(1):186-94. PubMed ID: 7516596
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Binding kinetics and bioassay of RRE mRNA fragments to a peptide containing the recognition domain of HIV-1 Rev.
    West ML; Ramsdale TE
    Biomed Pept Proteins Nucleic Acids; 1996-1997; 2(3):85-8. PubMed ID: 9575345
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In silico mutagenesis of RNA splicing in HIV-1.
    Kim H; Yin J
    Biotechnol Bioeng; 2005 Sep; 91(7):877-93. PubMed ID: 15937951
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term protection against HIV-1 infection conferred by tat or rev antisense RNA was affected by the design of the retroviral vector.
    Peng H; Callison D; Li P; Burrell C
    Virology; 1996 Jun; 220(2):377-89. PubMed ID: 8661389
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of the solution conformations of unbound and Tat peptide-bound forms of HIV-1 TAR RNA.
    Long KS; Crothers DM
    Biochemistry; 1999 Aug; 38(31):10059-69. PubMed ID: 10433713
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Probing the proximity of the core domain of an HIV-1 Tat fragment in a Tat-TAR complex by affinity cleaving.
    Huq I; Rana TM
    Biochemistry; 1997 Oct; 36(41):12592-9. PubMed ID: 9376365
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modulation of HTLV-I gene expression by HIV-1 Rev through an alternative RxRE-independent pathway mediated by the RU5 portion of the 5'-LTR.
    Kubota S; Furuta RA; Hatanaka M; Pomerantz RJ
    Biochem Biophys Res Commun; 1998 Feb; 243(1):79-85. PubMed ID: 9473483
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structure-based design of a dimeric RNA-peptide complex.
    Campisi DM; Calabro V; Frankel AD
    EMBO J; 2001 Jan; 20(1-2):178-86. PubMed ID: 11226168
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination gene therapy: synergistic inhibition of human immunodeficiency virus Tat and Rev functions by a single RNA molecule.
    Lisziewicz J; Zeng G; Gratas C; Weinstein JN; Lori F
    Hum Gene Ther; 2000 Apr; 11(6):807-15. PubMed ID: 10779158
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incorporation of an artificial protease and nuclease at the HIV-1 Tat binding site of trans-activation responsive RNA.
    Shah K; Neenhold H; Wang Z; Rana TM
    Bioconjug Chem; 1996; 7(3):283-9. PubMed ID: 8816949
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The HIV-1 Tat transactivator protein: a therapeutic target?
    Fulcher AJ; Jans DA
    IUBMB Life; 2003 Dec; 55(12):669-80. PubMed ID: 14769003
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bovine immunodeficiency virus tat gene: cloning of two distinct cDNAs and identification, characterization, and immunolocalization of the tat gene products.
    Fong SE; Greenwood JD; Williamson JC; Derse D; Pallansch LA; Copeland T; Rasmussen L; Mentzer A; Nagashima K; Tobin G; Gonda MA
    Virology; 1997 Jul; 233(2):339-57. PubMed ID: 9217057
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of the small leader exons 2 and 3 on human immunodeficiency virus type 1 gene expression.
    Krummheuer J; Lenz C; Kammler S; Scheid A; Schaal H
    Virology; 2001 Aug; 286(2):276-89. PubMed ID: 11485396
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.